Abstract 4569: D3S-003, an orally bioavailable potent and selective dual-state inhibitor targeting both GDP- and GTP-bound KRAS G12D
Jing Zhang, Tienan Wang, Robert A. Mook, Haibo Xie et autres
Abstract KRAS G12D is the most prevalent KRAS mutation in human cancers and represents a highly attractive yet challenging oncogenic target. Compared with KRAS G12C, the intrinsic hydrolysis rate of KRAS G12D is significantly slower, resulting in a more persistent active (GTP-bound) …
us (code pays fourni par la source)
0 citations
Cancer Research